TheraRadar
Landscape → Oncology

Esophageal Cancer Clinical Trial Landscape

Data updated: May 20, 2026

772 clinical trials tracked since 2008

Esophageal cancer develops in the lining of the esophagus, the tube that carries food from the throat to the stomach. It is a relatively uncommon cancer, but its incidence has been increasing in recent decades. Since 2008, 767 clinical trials have been registered to study esophageal cancer, with 415 trials currently active, meaning they are recruiting, enrolling, or active but not recruiting. The majority of active trials are in Phase 2, with 269 trials, compared to 75 active Phase 3 trials, suggesting a strong focus on mid-stage development. Phase 1 trials also represent a significant portion of the active pipeline, with 138 trials. AstraZeneca leads industry sponsorship of active trials with 10, followed by Merck with 6. Roche, Pfizer, and Seagen, a wholly owned subsidiary of Pfizer, each sponsor 3 active trials.

422 active
/
772 total (since 2008)
141
Phase 1 Active
271 total
274
Phase 2 Active
493 total
76
Phase 3 Active
130 total
4
Phase 4 Active
11 total

Top Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 10 1 0
Merck 6 6 0
Sichuan Baili Pharmaceutical Co., Ltd. 4 0 0
Roche 3 4 0
Pfizer 3 0 2

+ 10 more sponsors — see full table below

Featured Phase 3 Trials

NCT07522151 RECRUITING
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd n=874
NCT04210115 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Merck Sharp & Dohme LLC n=703
NCT06203600 RECRUITING
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI) n=224
NCT04550260 ACTIVE NOT RECRUITING
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
AstraZeneca n=640
NCT05677490 RECRUITING
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology n=382

+ 125 more Phase 3 trials — see full database below

Esophageal Cancer — Trials Started by Year (last 10 years)

2016
35
2017
32
2018
33
2019
47
2020
45
2021
52
2022
49
2023
70
2024
102
2025
94
2026
46

TheraRadar.com

Full Trial Database

Complete sponsor table, every trial across all phases, plus competitive analytics. Sortable, filterable, exportable for Pro users.

Top Sponsors (all-time)

AstraZeneca
11
Merck
12
Sichuan Baili Pharmaceutical Co., Ltd.
4
Roche
7
Pfizer
5
Seagen, a wholly owned subsidiary of Pfizer
4
AbbVie
3
SystImmune Inc.
3
Daiichi Sankyo
3
BeiGene
11

Active Trials by Phase

Phase 1
141
Phase 2
274
Phase 3
76
Phase 4
4

Enrollment Size Distribution

1-50
329
51-200
277
201-500
93
501-1k
40
1k+
8

All Industry Sponsors

Sorted by active Active Done Failed
AstraZeneca 10 1 0
Merck 6 6 0
Sichuan Baili Pharmaceutical Co., Ltd. 4 0 0
Roche 3 4 0
Pfizer 3 0 2
Seagen, a wholly owned subsidiary of Pfizer 3 1 0
AbbVie 3 0 0
SystImmune Inc. 3 0 0
Daiichi Sankyo 3 0 0
BeiGene 2 8 1
Eli Lilly 2 2 0
Suzhou Suncadia Biopharmaceuticals Co., Ltd. 2 0 1
NGM Biopharmaceuticals, Inc 2 1 0
Sunshine Lake Pharma Co., Ltd. 2 1 0
USWM CT, LLC 2 0 0
NCT07522151 RECRUITING
Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Cancer
Shanghai Shengdi Pharmaceutical Co., Ltd n=874
NCT04210115 ACTIVE NOT RECRUITING
Study of Pembrolizumab (MK-3475) Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy (MK-3475-975/KEYNOTE-975)
Merck Sharp & Dohme LLC n=703
NCT06203600 RECRUITING
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
National Cancer Institute (NCI) n=224
NCT04550260 ACTIVE NOT RECRUITING
Study of Durvalumab Versus Placebo in Combination With Definitive Chemoradiation Therapy in Patient With ESCC
AstraZeneca n=640
NCT05677490 RECRUITING
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
Alliance for Clinical Trials in Oncology n=382
NCT07000253 RECRUITING
Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=290
NCT03801876 RECRUITING
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
NRG Oncology n=300
NCT07221149 RECRUITING
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Bristol-Myers Squibb n=690
NCT04248452 ACTIVE NOT RECRUITING
Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body
ECOG-ACRIN Cancer Research Group n=314
NCT05357846 RECRUITING
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
Sun Yat-sen University n=422
NCT07554456 NOT YET RECRUITING
A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus Platinum-Based Chemotherapy Plus Tislelizumab as First-line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus02)
Sichuan Baili Pharmaceutical Co., Ltd. n=90
NCT07463573 RECRUITING
QLC5508 vs. Chemotherapy in Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Qilu Pharmaceutical Co., Ltd. n=466
NCT07177794 RECRUITING
Consolidation of Toripalimab and Capecitabine After Chemoradiotherapy in ESCC
Sun Yat-sen University n=242
NCT07217704 RECRUITING
Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.
SOFIE n=200
NCT06964568 RECRUITING
CCRT Followed by PD-1 Inhibitor Maintenance Therapy in Locally Advanced ESCC
Fudan University n=452
NCT04543617 ACTIVE NOT RECRUITING
A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy
Hoffmann-La Roche n=760
NCT06304974 ACTIVE NOT RECRUITING
A Study Comparing BL-B01D1 With Chemotherapy of Physician's Choice in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma(PANKU-Esophagus01)
Sichuan Baili Pharmaceutical Co., Ltd. n=497
NCT05152147 ACTIVE NOT RECRUITING
A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers
Jazz Pharmaceuticals n=920
NCT07431281 RECRUITING
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
AstraZeneca n=2,130
NCT07392892 RECRUITING
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Pfizer n=840
NCT04848753 ACTIVE NOT RECRUITING
Perioperative Toripalimab (JS001) Combined With Neoadjuvant Chemotherapy in Patients With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma
Shanghai Junshi Bioscience Co., Ltd. n=663
NCT07487896 NOT YET RECRUITING
A Study of YL201 Versus Investigator's Choice of Chemotherapy in Participants With Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-Line Therapy
MediLink Therapeutics (Suzhou) Co., Ltd. n=440
NCT06731478 RECRUITING
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
Daiichi Sankyo n=726
NCT06346392 RECRUITING
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
AstraZeneca n=572
NCT07446335 NOT YET RECRUITING
A Phase III Study of First-line Anlotinib Combined With Benmelstobart in Patients With Advanced Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital of Zhengzhou University n=578
NCT06721520 RECRUITING
Effectiveness of Methods for Pyloric Drainage in esophagecTomY: Botox vs. Pyloromyotomy
The Cleveland Clinic n=170
NCT07406815 NOT YET RECRUITING
The Value of Near-Infrared Fluorescence Imaging in the Protection of the Recurrent Laryngeal Nerve During Minimally Invasive Esophagectomy
Fujian Medical University Union Hospital n=144
NCT04871412 RECRUITING
The Thoracic Peri-Operative Integrative Surgical Care Evaluation Trial - Stage III
Ottawa Hospital Research Institute n=20
NCT06952621 NOT YET RECRUITING
Neoadjuvant Treatment of Toripalimab Combined With Nab-paclitaxel and Platinum Versus Neoadjuvant Docetaxel Combined With Cisplatin and 5-fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma
Tang-Du Hospital n=390
NCT07332221 NOT YET RECRUITING
Application of Toripalimab as Adjuvant Therapy After Esophageal Cancer Surgery: A Multicenter Clinical Trial
Henan Cancer Hospital n=435
NCT06644781 RECRUITING
A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)
Daiichi Sankyo n=510
NCT06676449 RECRUITING
TDLN-sparing RT Plus Immunotherapy and Chemotherapy in Locally Advanced ESCC
Fudan University n=432
NCT07306663 ACTIVE NOT RECRUITING
Sintilimab Combined With Chemotherapy Induction Therapy Followed by CCRT vs. CCRT for Esophageal Cancer: A Randomized Controlled Phase Ⅲ Clinical Study
Jiangsu Cancer Institute & Hospital n=242
NCT07303231 NOT YET RECRUITING
The Value of Indocyanine Green-guided Near-infrared Fluorescence Technology in Tracing Sentinel Lymph Nodes During Esophagectomy
Fujian Medical University Union Hospital n=144
NCT04949256 ACTIVE NOT RECRUITING
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Plus Chemotherapy in Participants With Metastatic Esophageal Carcinoma (MK-7902-014/E7080-G000-320/LEAP-014)
Merck Sharp & Dohme LLC n=864
NCT06914011 NOT YET RECRUITING
Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally Advanced Esophageal Squamous Cell Carcinoma
Asan Medical Center n=172
NCT07251062 NOT YET RECRUITING
A Study of SYS6010, Enlonstobart, and Chemotherapy for First-Line Treatment of Esophageal Squamous Cell Carcinoma.
CSPC Megalith Biopharmaceutical Co.,Ltd. n=737
NCT07246330 NOT YET RECRUITING
Stratified Treatment in Unresectable Locally Advanced ESCC Without Progression After Chemoimmunotherapy Induction Plus CCRT: Toripalimab Consolidation vs observation--a Prospective, Randomized, Controlled Phase III Multicenter Study
Tianjin Medical University Cancer Institute and Hospital n=340
NCT07211009 NOT YET RECRUITING
Patient-Reported Symptom Care Versus Usual Care After Esophageal Cancer Surgery: A Single-Center Phase 3 Randomized Trial
Sichuan University n=240
NCT07016737 ENROLLING BY INVITATION
Immunochemotherapy ± Salvage Chemoradiation for Local Recurrence of Esophageal Squamous Cell Carcinoma After Definitive Chemoradiotherapy
Ye jinjun n=79
NCT05078047 RECRUITING
Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO
UNICANCER n=646
NCT04328948 RECRUITING
A Randomized Controlled Trial Evaluating of Prophylactic Irradiation in CRT for cT1bN0M0 ESCC
National Cancer Center, Japan n=280
NCT04415853 RECRUITING
Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer
Sunshine Lake Pharma Co., Ltd. n=416
NCT06907602 RECRUITING
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell Carcinoma
Peking Union Medical College Hospital n=120
NCT04950322 ACTIVE NOT RECRUITING
A Trial of SHR1701 Plus Chemotherapy in Patients With Gastric or Gastroesophageal Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=737
NCT05504265 RECRUITING
Perioperative Analgesia Modes in Minimally Invasive Esophagectomy
Cancer Institute and Hospital, Chinese Academy of Medical Sciences n=102
NCT06861777 NOT YET RECRUITING
Total Neoadjuvant Therapy Combined With Adebrelimab in Locally Advanced Resectable ESCC
YIN LI n=474
NCT04460352 RECRUITING
Chemoradiotherapy Followed by Planned Surgery or by Surveillance and Surgery Only When Needed for Oesophageal Cancer
Karolinska University Hospital n=1,020
NCT05865743 RECRUITING
Perioperative SDD to Prevent Infectious Complications After Esophagectomy
Radboud University Medical Center n=854
NCT05055648 RECRUITING
PROton Versus Photon Therapy for Esophageal Cancer - a Trimodality Strategy
University of Aarhus n=396
NCT04513808 RECRUITING
Total Intravenous Anesthesia and Recurrence Free Survival
The Cleveland Clinic n=1,614
NCT05919030 RECRUITING
A Study of Chemoradiation in Combination with Tislelizumab As First Line Treatment in Participants with Advanced Esophageal Squamous Cell Carcinoma
Renmin Hospital of Wuhan University n=155
NCT05043688 RECRUITING
Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC.
Zhigang Li n=426
NCT05495152 RECRUITING
Adjuvant Sintilimab for Locally Advanced Esophageal Squamous Cell Carcinoma
Henan Cancer Hospital n=219
NCT06022861 RECRUITING
A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma
Shandong Boan Biotechnology Co., Ltd n=510
NCT06563869 RECRUITING
Sintilimab With Chemotherapy Plus PEG-rhG-GSF for Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma
The First Affiliated Hospital with Nanjing Medical University n=40
NCT06138028 RECRUITING
Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer
Qingdao Central Hospital n=90
NCT06501664 NOT YET RECRUITING
Liposomal Irinotecan and 5-FU as Second-line Therapy for Patients With ESCC
Rui-hua Xu, MD, PhD n=360
NCT06339060 RECRUITING
An Organ Preservation Strategies After Chemoradiotherapy Combined With Immunotherapy for Esophageal Cancer (PALACE3).
Ruijin Hospital n=356
NCT06411171 NOT YET RECRUITING
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:
xiaohua li n=36
NCT06418945 NOT YET RECRUITING
Clinical Study on the Effect of Removal of Porphyromonas Gingivalis on Prognosis of Esophageal Cancer After Radical Surgery
The First Affiliated Hospital of Henan University of Science and Technology n=500
NCT02509286 ACTIVE NOT RECRUITING
Perioperative Chemotherapy Compared To Neoadjuvant Chemoradiation in Patients With Adenocarcinoma of the Esophagus
University Hospital Schleswig-Holstein n=438
NCT06190782 RECRUITING
Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor
Fudan University n=354
NCT06354530 RECRUITING
A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma
Army Medical Center of PLA n=266
NCT06194734 RECRUITING
A Study of KC1036 Versus Investigator's Choice of Chemotherapy in Patients With Advanced Esophageal Cancer
Beijing Konruns Pharmaceutical Co., Ltd. n=490
NCT06115629 NOT YET RECRUITING
Surveillance After Resection of Oesophageal aNd Gastric Cancer (SARONG-II) Trial
University of Dublin, Trinity College n=952
NCT05244798 NOT YET RECRUITING
Sintilimab Plus NCT or NCRT Versus NCRT for ESCC
Sichuan Cancer Hospital and Research Institute n=420
NCT05547529 RECRUITING
The Efficacy of Neoadjuvant Chemoradiotherapy in Comparison With Neoadjuvant Chemotherapy in Patients With Resectable Squamous Cell Esophageal Cancer
Blokhin's Russian Cancer Research Center n=156
NCT04280822 RECRUITING
Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma
Henan Cancer Hospital n=400
NCT04138212 RECRUITING
Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy for Resectable Locally Advanced Esophageal Cancer (HCHTOG1903)
Henan Cancer Hospital n=456
NCT04973306 RECRUITING
Neoadjuvant Immunotherapy Plus CRT Versus Neoadjuvant CRT for Locally Advanced Resectable ESCC
Shanghai Zhongshan Hospital n=176
NCT05188313 RECRUITING
TRAstuzumab and Pertuzumab for HER2+ Resectable Oesophageal Cancer
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) n=376
NCT04807673 RECRUITING
Pembrolizumab Plus Neoadjuvant Chemotherapy vs. Neoadjuvant Chemoradiotherapy for Locally Advanced ESCC (KEYSTONE-002)
Tianjin Medical University Cancer Institute and Hospital n=342
NCT04009265 RECRUITING
Study Compare Adjuvant Chemotherapy, Chemoradiotherapy and Surgery Alone for pN1-2(pT1b-3N1-2M0) Esophageal Carcinoma
Fujian Medical University Union Hospital n=819
NCT04135664 RECRUITING
Comparison of Esophagectomy and Chemoradiation for Patients With cN0-pT1b Stage Esophageal Squamous Cell Carcinoma
Shanghai Chest Hospital n=176
NCT03731442 RECRUITING
Salvage Chemoradiation Therapy for Recurrence After Radical Surgery or Palliative Surgery in Esophageal Cancer Patients
Chinese Academy of Medical Sciences n=300
NCT03604991 SUSPENDED
Nivolumab and Ipilimumab in Treating Patients With Esophageal and Gastroesophageal Junction Adenocarcinoma Undergoing Surgery
National Cancer Institute (NCI) n=278
NCT03957590 COMPLETED
A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma
BeiGene n=370
NCT04540211 COMPLETED
A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma
Hoffmann-La Roche n=461
NCT04689594 TERMINATED
A Study to Evaluate the Esophageal Stenosis Inhibition Effects of CLS2702C/CLS2702D After Endoscopic Submucosal Dissection (ESD) in Patients With Superficial Esophageal Cancer in the Steroid Administration Risk Group
CellSeed Inc. n=1
NCT03221426 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)
Merck Sharp & Dohme LLC n=1,007
NCT04882241 COMPLETED
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China Extension
Merck Sharp & Dohme LLC n=120
NCT01196390 COMPLETED
Radiation Therapy, Paclitaxel, and Carboplatin With or Without Trastuzumab in Treating Patients With Esophageal Cancer
National Cancer Institute (NCI) n=203
NCT05149807 TERMINATED
Clinical Study of SHR-1701 Plus Chemotherapy as Perioperative Treatment in Subjects With Gastric Cancer
Suzhou Suncadia Biopharmaceuticals Co., Ltd. n=81
NCT02872116 COMPLETED
Efficacy Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Against Chemotherapy in Stomach Cancer or Stomach/Esophagus Junction Cancer
Bristol-Myers Squibb n=2,031
NCT03783442 COMPLETED
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene n=649
NCT04082364 COMPLETED
Combination Margetuximab, Retifanlimab, Tebotelimab, and Chemotherapy Phase 2/3 Trial in HER2+ Gastric/GEJ Cancer
MacroGenics n=82
NCT01249352 COMPLETED
A Study of Chemoradiation Associated with Nimotuzumab As the Treatment of Locally Advanced Esophageal Cancer
Eurofarma Laboratorios S.A. n=104
NCT02349412 COMPLETED
Early Palliative Care With Standard Care or Standard Care Alone in Improving Quality of Life of Patients With Incurable Lung or Non-colorectal Gastrointestinal Cancer and Their Family Caregivers
Alliance for Clinical Trials in Oncology n=405
NCT04499924 COMPLETED
Tucatinib, Trastuzumab, Ramucirumab, and Paclitaxel Versus Paclitaxel and Ramucirumab in Previously Treated HER2+ Gastroesophageal Cancer
Seagen Inc. n=17
NCT06775652 COMPLETED
Neoadjuvant Chemoradiotherapy Plus Surgery vs. Surgery Plus Adjuvant Therapy for ESCC
Yongtao Han n=254
NCT03430843 COMPLETED
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
BeiGene n=512
NCT05369234 COMPLETED
Effects of Oral Aloe Vera Juice on Chemotherapy and Radiation-induced Oral Mucositis and Esophagitis
Covenant Health Cancer Center n=100
NCT01404156 COMPLETED
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
Dr. Gordon Buduhan n=29
NCT04029857 WITHDRAWN
Nutritional Supplementation in Reducing Complications in Patients With Locally Advanced Esophageal Cancer Undergoing Chemotherapy, Radiation Therapy, and/or Surgery
M.D. Anderson Cancer Center
NCT03099382 COMPLETED
Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd. n=457
NCT03600831 COMPLETED
Postoperative Concurrent Chemoradiotherapy Versus Radiotherapy Alone for Patients With Locoregionally Advanced Esophageal Squamous Cell Carcinoma
Huai'an First People's Hospital n=434
NCT04187352 COMPLETED
A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma
CStone Pharmaceuticals n=540
NCT02178956 COMPLETED
A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer
Sumitomo Pharma America, Inc. n=714
NCT03748134 COMPLETED
Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )
Innovent Biologics (Suzhou) Co. Ltd. n=746
NCT02853474 COMPLETED
Early Palliative Care in Patients With Metastatic Upper Gastrointestinal Cancers Treated With First-line Chemotherapy
Centre Oscar Lambret n=480
NCT03933449 COMPLETED
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal/Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)-China Extension Study
Merck Sharp & Dohme LLC n=123
NCT02564263 COMPLETED
Study of Pembrolizumab (MK-3475) Versus Investigator's Choice Standard Therapy for Participants With Advanced Esophageal/ Esophagogastric Junction Carcinoma That Progressed After First-Line Therapy (MK-3475-181/KEYNOTE-181)
Merck Sharp & Dohme LLC n=628
NCT03691090 COMPLETED
Study of SHR-1210 in Combination With Chemotherapy in Advanced Esophageal Cancer
Jiangsu HengRui Medicine Co., Ltd. n=596
NCT02661971 COMPLETED
FLOT vs. FLOT/Ramucirumab for Perioperative Therapy of Gastric or GEJ Cancer (RAMSES)
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=180
NCT02569242 COMPLETED
Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer
Ono Pharmaceutical Co., Ltd. n=419
NCT00655876 COMPLETED
Paclitaxel, Cisplatin, and Radiation Therapy With or Without Cetuximab in Treating Patients With Locally Advanced Esophageal Cancer
Radiation Therapy Oncology Group n=344
NCT01137123 COMPLETED
Improve the Treatment of Thoracic Esophageal Cancer
Sun Yat-sen University n=301
NCT02459457 COMPLETED
A Comparison of Paclitaxel-based Three Regimens Concurrent With Radiotherapy for Patients With Local Advanced Esophageal Cancer
Fudan University n=321
NCT02326779 WITHDRAWN
Low-dose Aspirin Therapy for Esophageal Cancer
Zhejiang University
NCT02272699 WITHDRAWN
Neoadjuvant Treatment of Nimotuzumab With Chemotherapy or Radiotherapy in Resectable Esophageal Squamous Cell Carcinoma
Peking University
NCT02644408 COMPLETED
Megestrol Acetate for the Improvement of Quality of Life in Esophageal Cancer With Chemoradiotherapy
The First Affiliated Hospital of Henan University of Science and Technology n=184
NCT01107639 COMPLETED
Radiation Therapy and Chemotherapy, With or Without Cetuximab, Followed by Surgery in Treating Patients With Locally Advanced Esophageal Cancer That Can Be Removed by Surgery
Swiss Cancer Institute n=297
NCT02813967 COMPLETED
S-1 Concurrent With Radiotherapy Versus Radiotherapy for Elderly Patients With Esophageal Cancer
Zhejiang Cancer Hospital n=298
NCT02581462 COMPLETED
FLOT vs. FLOT/Herceptin/Pertuzumab for Perioperative Therapy of HER-2 Expressing Gastric or GEJ Cancer
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest n=81
NCT01544790 COMPLETED
Robot-assisted Thoraco-laparoscopic Esophagectomy Versus Open Transthoracic Esophagectomy
UMC Utrecht n=112
NCT02399306 COMPLETED
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
Sichuan Cancer Hospital and Research Institute n=222
NCT01348217 COMPLETED
Radiochemotherapy With and Without Dose Escalation in Patients Presenting Locally Advanced or Inoperable Carcinoma of the Oesophagus
Centre Georges Francois Leclerc n=196
NCT02866019 COMPLETED
Human (Autologous) Oral Mucosal Cell Sheet Transplantation After ESD in Patients With Superficial Esophageal Cancer
CellSeed Inc. n=10
NCT01446874 TERMINATED
Prevention of Post-operative Pneumonia (POPP)
Washington University School of Medicine n=150
NCT01591135 COMPLETED
A Phase III Study of Comparing Paclitaxel Plus 5-Fluorouracil Versus Cisplatin Plus 5-Fluorouracil in Chemoradiotherapy for Locally Advanced Esophageal Carcinoma
Fudan University n=436
NCT01813253 TERMINATED
Phase 3 Study of Nimotuzumab and Irinotecan as Second Line With Advanced or Recurrect Gastric and Gastroesophageal Junction Cancer
Kuhnil Pharmaceutical Co., Ltd. n=400
NCT01740375 TERMINATED
Role of Esophagectomy in Complete Responders to CCRT
Asan Medical Center n=486
NCT00160875 COMPLETED
Pre-operative Chemo (CPT11, Cisplatin), Radiotherapy, Plus Surgery for Resectable Esophageal Cancer
University Health Network, Toronto n=54
NCT01704690 TERMINATED
Combination Treatment of S-1 With Paclitaxel in Advanced Esophageal Cancer
Peking University n=4
NCT00861094 COMPLETED
Radiation Therapy + Combination Chemotherapy as 1st-Line Therapy for Patients With Inoperable Esophageal Cancer
UNICANCER n=266
NCT01998347 WITHDRAWN
Paclitaxel Liposome and Cisplatin as First-line Chemotherapy in Patients With Metastatic Esophageal Cancer
Shantou University Medical College
NCT01998230 COMPLETED
Early Oral Feeding Following Thoracolaparoscopic Oesophagectomy in Patients With Esophageal Cancer
Yin Li n=280
NCT00978549 COMPLETED
Symptom Control With or Without Docetaxel in Treating Patients With Relapsed Esophageal Cancer or Stomach Cancer
Cambridge University Hospitals NHS Foundation Trust n=320
NCT01243398 COMPLETED
Gefitinib in Treating Patients With Esophageal Cancer That is Progressing After Chemotherapy
University of Oxford n=450

Full Esophageal Cancer Pipeline

Every sponsor, every trial across Phase 1–4. Sortable, filterable, exportable.

Unlock with Pro

Data: ClinicalTrials.gov · Trials registered 2008 onwards · Industry sponsors only